NasdaqGM:TNXP

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing drugs and biologics to treat various diseases.


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Tonix Pharmaceuticals Holding's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TNXP has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

8.2%

TNXP

0.4%

US Biotechs

2.3%

US Market


1 Year Return

-93.3%

TNXP

28.5%

US Biotechs

6.7%

US Market

Return vs Industry: TNXP underperformed the US Biotechs industry which returned 28.5% over the past year.

Return vs Market: TNXP underperformed the US Market which returned 6.7% over the past year.


Shareholder returns

TNXPIndustryMarket
7 Day8.2%0.4%2.3%
30 Day2.8%10.3%6.0%
90 Day-19.8%23.2%18.9%
1 Year-93.3%-93.3%29.8%28.5%9.0%6.7%
3 Year-99.9%-99.9%31.8%27.5%36.6%27.7%
5 Year-100.0%-100.0%-5.1%-10.5%64.2%46.1%

Price Volatility Vs. Market

How volatile is Tonix Pharmaceuticals Holding's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Tonix Pharmaceuticals Holding undervalued compared to its fair value and its price relative to the market?

1.01x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TNXP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TNXP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TNXP is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: TNXP is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TNXP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TNXP is good value based on its PB Ratio (1x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Tonix Pharmaceuticals Holding forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

2.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TNXP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TNXP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TNXP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if TNXP's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if TNXP's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TNXP's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Tonix Pharmaceuticals Holding performed over the past 5 years?

10.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TNXP is currently unprofitable.

Growing Profit Margin: TNXP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TNXP is unprofitable, but has reduced losses over the past 5 years at a rate of 10.5% per year.

Accelerating Growth: Unable to compare TNXP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TNXP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: TNXP has a negative Return on Equity (-94.91%), as it is currently unprofitable.


Next Steps

Financial Health

How is Tonix Pharmaceuticals Holding's financial position?


Financial Position Analysis

Short Term Liabilities: TNXP's short term assets ($33.4M) exceed its short term liabilities ($2.7M).

Long Term Liabilities: TNXP's short term assets ($33.4M) exceed its long term liabilities ($25.0K).


Debt to Equity History and Analysis

Debt Level: TNXP is debt free.

Reducing Debt: TNXP had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TNXP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: TNXP has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 1.4% each year.


Next Steps

Dividend

What is Tonix Pharmaceuticals Holding current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TNXP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TNXP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TNXP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TNXP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TNXP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Seth Lederman (62yo)

8.75yrs

Tenure

US$1,288,273

Compensation

Dr. Seth Lederman, M.D., is a Co-Founder of Tonix Pharmaceuticals Holding Corp. (formerly, Krele Pharmaceuticals) and has been its Chairman, Chief Executive Officer, President and Director since October 7, ...


CEO Compensation Analysis

Compensation vs Market: Seth's total compensation ($USD1.29M) is above average for companies of similar size in the US market ($USD612.38K).

Compensation vs Earnings: Seth's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Seth Lederman
Co-Founder8.75yrsUS$1.29m0.046% $15.4k
Bradley Saenger
CFO & Treasurer4.42yrsUS$578.11k0.0027% $896.4
Gregory Sullivan
Chief Medical Officer & Secretary3.33yrsUS$652.39k0.0027% $899.8
Jessica Morris
Chief Operating Officer4.42yrsUS$418.21k0.000030% $10.1
Ronald Notvest
Executive Vice President of Commercial Planning and Development4.42yrsno datano data
Herbert Harris
Executive Vice President of Translational Medicine0.17yrno datano data
Daniel Clauw
Consultantno datano datano data
R. Gendreau
Consultantno datano datano data

4.4yrs

Average Tenure

58yo

Average Age

Experienced Management: TNXP's management team is considered experienced (4.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Seth Lederman
Co-Founder8.75yrsUS$1.29m0.046% $15.4k
Adeoye Olukotun
Independent Director1.83yrsUS$49.44kno data
David Grange
Independent Director2.42yrsUS$49.44kno data
Daniel Goodman
Independent Director1.17yrsUS$49.44kno data
Margaret Bell
Independent Director2.83yrsUS$49.44kno data
Richard Bagger
Director0.083yrno datano data
Iredell Iglehart
Member of Scientific Advisory Boardno datano datano data
James Treco
Independent Lead Director0.33yrUS$64.28kno data
Harvey Moldofsky
Member of Scientific Advisory Board9.08yrsno datano data

2.1yrs

Average Tenure

62yo

Average Age

Experienced Board: TNXP's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 8188.4%.


Top Shareholders

Company Information

Tonix Pharmaceuticals Holding Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Tonix Pharmaceuticals Holding Corp.
  • Ticker: TNXP
  • Exchange: NasdaqGM
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$33.701m
  • Shares outstanding: 52.53m
  • Website: https://www.tonixpharma.com

Number of Employees


Location

  • Tonix Pharmaceuticals Holding Corp.
  • 509 Madison Avenue
  • Suite 1608
  • New York
  • New York
  • 10022
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TNXPNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDOct 2011
TPMRDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2011

Biography

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing drugs and biologics to treat various diseases. Its lead product candidate is TNX-102 SL, a proprietary cyclobenzaprine HCl sublingual tablets as a bedtime administration, which is in Phase III clinical trial for the treatment of posttraumatic stress disorder (PTSD) and fibromyalgia; Phase II development for the treatment of agitation in Alzheimer’s disease; and Phase II proof-of-concept study for the treatment of alcohol use disorder. The company is also developing TNX-601 (tianeptine oxalate) that is in pre-investigational new drug application stage for the treatment of PTSD and neurocognitive dysfunction associated with corticosteroid; TNX-1300 for the treatment of cocaine intoxication; and TNX-801, a smallpox-preventing vaccine, which is in preclinical stage based on synthetic version of live horsepox virus. In addition, its other preclinical product candidates include TNX-1600 for the treatment of PTSD, and depression and attention deficit hyperactivity disorder; TNX-1500 for prevention and treatment of organ transplant rejection, as well as for autoimmune conditions, such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis; and TNX-1700 for gastric and pancreatic cancers. Tonix Pharmaceuticals Holding Corp. has a research collaboration agreement with Massachusetts General Hospital for testing TNX-1500 for the prevention of organ transplant rejection; and a strategic collaboration with Southern Research Institute to support the development of TNX-1800, a vaccine to protect against COVID-19. The company was founded in 2007 and is based in New York, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/13 07:47
End of Day Share Price2020/07/10 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.